Anumana Receives FDA Clearance for Cardiac Amyloidosis Algorithm

The AI-powered ECG tool is the first of its kind to receive regulatory approval.

Apr. 8, 2026 at 5:45pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image of a human heart, with intricate details of the cardiac structure and blood vessels visible, conveying the complex nature of the organ and the potential for advanced diagnostic technologies to identify early signs of cardiac disease.Anumana's AI-powered ECG algorithm offers a new tool for detecting the early signs of cardiac amyloidosis, a rare and serious heart condition.Cambridge Today

Anumana, a healthcare technology company, has received the first and only FDA clearance for its ECG-AI algorithm designed to detect cardiac amyloidosis, a rare and serious condition that affects the heart. The algorithm uses standard 12-lead electrocardiogram (ECG) data to identify signs of the disease, providing a new diagnostic tool for clinicians.

Why it matters

Cardiac amyloidosis is often underdiagnosed due to the complexity of current detection methods. Anumana's AI-powered ECG tool offers a more accessible and scalable way to screen for the condition, which can lead to earlier intervention and improved patient outcomes.

The details

Anumana's ECG-AI algorithm analyzes standard 12-lead ECG data to identify patterns indicative of cardiac amyloidosis. The tool is designed to be used in conjunction with other diagnostic tests to provide a comprehensive assessment of a patient's condition. By leveraging AI, the algorithm can detect subtle changes in the electrical activity of the heart that may be missed by human clinicians.

  • Anumana announced the FDA clearance on April 8, 2026.

The players

Anumana

A healthcare technology company that develops AI-powered diagnostic tools, including the ECG-AI algorithm for cardiac amyloidosis.

Got photos? Submit your photos here. ›

What’s next

With the FDA clearance, Anumana plans to make the ECG-AI algorithm available to healthcare providers across the United States, expanding access to this innovative diagnostic tool.

The takeaway

Anumana's FDA-cleared ECG-AI algorithm represents a significant advancement in the early detection of cardiac amyloidosis, a condition that can be challenging to diagnose. This technology has the potential to improve patient outcomes by enabling more timely diagnosis and treatment.